drugset

drugset / Trial / NCT07464587

Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

NCT07464587 ↗

Phase 3 Not yet recruiting 800 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease

Timeline

Start: 2026-03
Primary completion: 2027-02
Completion: 2027-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQC3721	Unknown	6 mg	Inhaled

Indications